Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality

Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality

Background. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (abemaciclib, palbociclib, ribociclib) plus aromatase inhibitors (AI) are the modern standard-of-care of the first-line treatment of hormone-dependent (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).Aim. To evaluate the effects of...

Full description

Saved in:
Bibliographic Details
Main Authors: N. A. Avxentyev, E. V. Bilan, A. Yu. Goryainova, Yu. V. Makarova, R. A. Murashko, A. V. Sobolev, S. V. Sharov, D. Yu. Yukalchuk
Format: Article
Language:Russian
Published: ABV-press 2025-05-01
Series:Опухоли женской репродуктивной системы
Subjects:
breast cancer
palbociclib
ribociclib
abemaciclib
overall survival
cancer mortality
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1348
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://ojrs.abvpress.ru/ojrs/article/view/1348

Similar Items